1. Home
  2. ACRV

as of 12-01-2025 3:41pm EST

$2.39
+$0.03
+1.27%
Stocks Health Care Medicinal Chemicals and Botanical Products Nasdaq

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Chart Type:
Time Range:
Founded: 2018 Country:
United States
United States
Employees: N/A City: WATERTOWN
Market Cap: 74.5M IPO Year: 2022
Target Price: $14.67 AVG Volume (30 days): 1.3M
Analyst Decision: Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.13 EPS Growth: N/A
52 Week Low/High: $1.05 - $8.00 Next Earning Date: 11-13-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 805.34%

AI-Powered ACRV Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 77.69%
77.69%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Acrivon Therapeutics Inc. News

ACRV Breaking Stock News: Dive into ACRV Ticker-Specific Updates for Smart Investing

All ACRV News

Share on Social Networks: